Side effects of botox under eyes

On trend. Could a new trend of treatments using microcurrents by skin expert Shamara Bondaroff in New York, be the end of botox?

The Hylagen Blog

After having pratised baby botox for years, the year-olds of Manhattan are rediscovering the microcurrent, consisting in small painless electric pulses smoothing out wrinkles without any side effects. It's like Pilates for the face.

Today, the practice has evolved and is much more refined.

It accelerates the production of amino acids and stimulates cell regeneration. It also rehabilitates the facial muscles by tensing them slightly and stimulating collagen growth and blood circulation. Shamara created a protocol that includes exfoliation and LED therapy as well as massages carried out with natural serums.

The results? The eyelids to the bottom of the face appear lifted, and complexion is noticeably smoother.

Could botox be on its way out?

And fine lines and dark under-eye circles are no longer visible. It's the perfect treatment to use in conjunction with botox, which smoothes wrinkles by freezing muscles.

Il suffirait d'un gramme d'aérosol pour tuer au moins 1,5 million de personnes. Cette substance est fabriquée par une bactérie, le Clostridium botulinum, lorsqu'elle est infectée par un virus.

En thérapie, la toxine botulique, utilisée bien évidemment à des doses infimes de l'ordre de quelques nanogrammessupprime pour plusieurs semaines la transmission de l'influx nerveux et produit un affaiblissement musculaire au lieu de l'injection. Ce traitement s'est imposé ces dernières années pour traiter les dystonies focales.

Les résultats sont moins bons dans la crampe des écrivains. Botulinum toxin type A is the most potent of the 7 serotypes produced by the anaerobic bacterium Clostridium botulinum. Minute quantities of botulinum toxin type A offer significant potential in treating a wide variety of disorders associated with muscle overactivity.

History of Botulinum Toxin Type A Work with botulinum toxin type A as a therapeutic agent to treat human disease began in the late s through the collaboration of Alan B. Schantz, PhD, director of food microbiology and toxicology at the University of Wisconsin.